1 April

Kidney Int Suppl http://www.kisupplements.org/

• 00:00
  Table of Contents Kidney Int Suppl
  (Kidney International Supplements 12, 1 (2022))
• 00:00
  Title Page Kidney Int Suppl
  (Kidney International Supplements 12, 1 (2022))
• 00:00
  Subscription Information Kidney Int Suppl
  (Kidney International Supplements 12, 1 (2022))
• 00:00
  Editorial Board Kidney Int Suppl
  (Kidney International Supplements 12, 1 (2022))
• 00:00
  Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists—unmet needs and underserved patient cohorts - Murray Epstein Kidney Int Suppl
  The recent successful demonstrations that the nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone provides effective kidney and cardiovascular (CV) protection in patients with chronic kidney disease (CKD) and type 2 diabetes constitutes a platform for considering and implementing (...) (Kidney International Supplements 12, 1 (2022))
• 00:00
  Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: an extraordinary paradigm shift - Murray Epstein Kidney Int Suppl
  The past 90 years have witnessed an extraordinary trajectory of scientific discovery relating to aldosterone and mineralocorticoid receptor (MR) activation, and a profound reappraisal of their physiological and pathophysiological roles. Although most reviews hark back to 1953 and the isolation (...) (Kidney International Supplements 12, 1 (2022))
• 00:00
  The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis - James M. Luther, Agnes B. Fogo Kidney Int Suppl
  Chronic kidney disease is characterized by progressive scarring that results in loss of normal tissue in the kidney and eventually end-stage kidney disease. Interstitial fibrosis and tubular atrophy have been most closely correlated with decline in renal function. Potential mechanisms include (...) (Kidney International Supplements 12, 1 (2022))
• 00:00
  Clinical perspective—evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes - Peter Rossing Kidney Int Suppl
  Chronic kidney disease (CKD) in type 2 diabetes is a large and growing problem leading to end-stage kidney disease, atherosclerotic cardiovascular disease, and heart failure (HF). Aldosterone is a key risk factor in promoting inflammation and fibrosis, which causes cardiorenal failure. (...) (Kidney International Supplements 12, 1 (2022))
• 00:00
  Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease - Toshifumi Nakamura, Sophie Girerd, Frederic Jaisser, Jonatan Barrera-Chimal Kidney Int Suppl
  Chronic kidney disease is a major global health challenge, and mineralocorticoid receptor (MR) signaling is thought to play a role in disease progression. The classic role of the MR is the regulation of fluid and electrolyte homeostasis via differential gene expression, and recently its role in (...) (Kidney International Supplements 12, 1 (2022))
• 00:00
  Epidemiology of chronic kidney disease: an update 2022 - Csaba P. Kovesdy Kidney Int Suppl
  Chronic kidney disease is a progressive condition that affects >10% of the general population worldwide, amounting to >800 million individuals. Chronic kidney disease is more prevalent in older individuals, women, racial minorities, and in people experiencing diabetes mellitus and (...) (Kidney International Supplements 12, 1 (2022))
• 00:00
  The renin–angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts - Carlos M. Ferrario, Leanne Groban, Hao Wang, Xuming Sun, Jessica L. VonCannon, Kendra N. Wright, Sarfaraz Ahmad Kidney Int Suppl
  A large body of evidence implicates the renin–angiotensin system in the pathogenesis of cardiovascular disease. However, not everyone understands that the magnitude of the risk reduction achieved in clinical trials with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (...) (Kidney International Supplements 12, 1 (2022))
• 00:00
  Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms - Johann Bauersachs, Achim Lother Kidney Int Suppl
  Aldosterone controls salt–water homeostasis by acting on the mineralocorticoid receptor (MR), a ligand-activated transcription factor, in kidney epithelial cells. However, it is now evident that the MR is expressed in multiple cell types and tissues, acting as a key driver of cardiovascular (...) (Kidney International Supplements 12, 1 (2022))
• 00:00
  The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets - Morley D. Hollenberg, Murray Epstein Kidney Int Suppl
  The coronavirus disease 2019 (COVID-19) pandemic, causing considerable mortality and morbidity worldwide, has fully engaged the biomedical community in attempts to elucidate the pathophysiology of COVID-19 and develop robust therapeutic strategies. To this end, the predominant research focus (...) (Kidney International Supplements 12, 1 (2022))